These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 29716919)

  • 21. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against
    Fujimura T; Furugaki K; Harada N; Yoshimura Y
    Cancer Biol Ther; 2020 Sep; 21(9):863-870. PubMed ID: 32835580
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
    Thangavel C; Boopathi E; Liu Y; McNair C; Haber A; Perepelyuk M; Bhardwaj A; Addya S; Ertel A; Shoyele S; Birbe R; Salvino JM; Dicker AP; Knudsen KE; Den RB
    Clin Cancer Res; 2018 Mar; 24(6):1402-1414. PubMed ID: 29311118
    [No Abstract]   [Full Text] [Related]  

  • 23. JHD205, A Novel Abemaciclib Derivative, Exerts Antitumor Effects on Breast Cancer by CDK4/6.
    Ji J; Qin J; Wang X; Lv M; Hou X; Jing A; Zhou J; Zuo L; Liu W; Feng J; Qian Q; Liu Y; Wang X; Liu B
    Anticancer Agents Med Chem; 2024; 24(6):400-411. PubMed ID: 38192142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
    Gong X; Litchfield LM; Webster Y; Chio LC; Wong SS; Stewart TR; Dowless M; Dempsey J; Zeng Y; Torres R; Boehnke K; Mur C; Marugán C; Baquero C; Yu C; Bray SM; Wulur IH; Bi C; Chu S; Qian HR; Iversen PW; Merzoug FF; Ye XS; Reinhard C; De Dios A; Du J; Caldwell CW; Lallena MJ; Beckmann RP; Buchanan SG
    Cancer Cell; 2017 Dec; 32(6):761-776.e6. PubMed ID: 29232554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.
    Hashizume R; Zhang A; Mueller S; Prados MD; Lulla RR; Goldman S; Saratsis AM; Mazar AP; Stegh AH; Cheng SY; Horbinski C; Haas-Kogan DA; Sarkaria JN; Waldman T; James CD
    Neuro Oncol; 2016 Nov; 18(11):1519-1528. PubMed ID: 27370397
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition.
    Nasser AM; Melamed L; Wetzel EA; Chang JC; Nagashima H; Kitagawa Y; Muzyka L; Wakimoto H; Cahill DP; Miller JJ
    Clin Cancer Res; 2024 Jul; 30(14):2996-3005. PubMed ID: 38718141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor.
    Zhang Y; Li Y; Han Y; Li M; Li X; Fan F; Liu H; Li S
    Eur J Pharmacol; 2023 Apr; 945():175571. PubMed ID: 36804545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
    Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
    Pesch AM; Hirsh NH; Chandler BC; Michmerhuizen AR; Ritter CL; Androsiglio MP; Wilder-Romans K; Liu M; Gersch CL; Larios JM; Pierce LJ; Rae JM; Speers CW
    Clin Cancer Res; 2020 Dec; 26(24):6568-6580. PubMed ID: 32967938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
    Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
    Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer.
    Sharma A; Bender S; Zimmermann M; Riesterer O; Broggini-Tenzer A; Pruschy MN
    Clin Cancer Res; 2016 Sep; 22(17):4428-39. PubMed ID: 27076628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes.
    Hino H; Iriyama N; Kokuba H; Kazama H; Moriya S; Takano N; Hiramoto M; Aizawa S; Miyazawa K
    Cancer Sci; 2020 Jun; 111(6):2132-2145. PubMed ID: 32304130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer].
    Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual
    Wood AC; Krytska K; Ryles HT; Infarinato NR; Sano R; Hansel TD; Hart LS; King FJ; Smith TR; Ainscow E; Grandinetti KB; Tuntland T; Kim S; Caponigro G; He YQ; Krupa S; Li N; Harris JL; Mossé YP
    Clin Cancer Res; 2017 Jun; 23(11):2856-2868. PubMed ID: 27986745
    [No Abstract]   [Full Text] [Related]  

  • 40. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells.
    Cao Y; Li X; Kong S; Shang S; Qi Y
    J Cell Mol Med; 2020 May; 24(9):5135-5145. PubMed ID: 32277580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.